Besponsa (Inotuzumab Ozogamicin) Trial Overview & Conclusions - Hagop M. Kantarjian, MD - 102191

Spotlight
Video

Besponsa (Inotuzumab Ozogamicin) Trial Overview & Conclusions - Hagop M. Kantarjian, MD

Cancer-News has 103 videos Subscribe Here

Loading........
Description: Hagop M. Kantarjian, MD of MD Anderson Cancer Center's Department of Leukemia gives the trial overview and conclusions of Pfizer's newly approved FDA CD22-directed antibody-drug conjugate Besponsa (Inotuzumab Ozogamicin) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Shared By : Cancer-News
Posted on : 08/29/17
Added : 11 months ago